Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
0.9636
-0.1064 (-9.94%)
May 26, 2026, 3:31 PM EDT - Market open
Rani Therapeutics Holdings Employees
As of December 31, 2025, Rani Therapeutics Holdings had 71 total employees, including 69 full-time and 2 part-time employees. The number of employees decreased by 35 or -33.02% compared to the previous year.
Employees
71
Change (1Y)
-35
Growth (1Y)
-33.02%
Revenue / Employee
$44,634
Profits / Employee
-$414,676
Market Cap
96.18M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 71 | -35 | -33.02% | 69 | 2 |
| Dec 31, 2024 | 106 | -34 | -24.29% | 105 | 1 |
| Dec 31, 2023 | 140 | -23 | -14.11% | 140 | 0 |
| Dec 31, 2022 | 163 | 49 | 42.98% | 163 | 0 |
| Dec 31, 2021 | 114 | 43 | 60.56% | 114 | 0 |
| Sep 30, 2021 | 91 | 20 | 28.17% | 91 | 0 |
| Jun 30, 2021 | 78 | - | - | 78 | 0 |
| Mar 31, 2021 | 71 | - | - | 71 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pelthos Therapeutics | 92 |
| PolyPid | 75 |
| ImmuCell | 73 |
| Biomea Fusion | 41 |
| Oncolytics Biotech | 29 |
| Edesa Biotech | 17 |
| ProMIS Neurosciences | 11 |
| Rein Therapeutics | 10 |
RANI News
- 7 hours ago - Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 10 days ago - Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition - GlobeNewsWire
- 11 days ago - Rani Therapeutics Holdings Quarterly report: Q1 2026 - Filings
- 11 days ago - Rani Therapeutics Holdings Earnings release: Q1 2026 - Filings
- 13 days ago - Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference - GlobeNewsWire
- 5 weeks ago - Rani Therapeutics Holdings Proxy statement: Proxy filing - Filings
- 5 weeks ago - Rani Therapeutics Holdings Proxy statement: Proxy filing - Filings
- 6 weeks ago - Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy - GlobeNewsWire